Immunogenicity and Safety of a 9-Valent HPV Vaccine

This study is first analysis of 9vHPV vaccine immunogenicity in girls and boys 9 to 15 years of age. Seroconversion for all 9 HPV vaccine types was achieved in 99% of them and antibody responses was shown to be noninferior to those observed in 16- to 26-year-old young women.

16-26-year women were the population used to establish 9vHPV vaccine efficacy. The researchers suggest that their current findings support the bridging of efficacy findings from 16- to 26-year-old women to 9 to 15-year-old boys and girls.

 

Currently in the UK, Gardasil®, the quadrivalent vaccine which contains Virus-like particles for four HPV types (6, 11, 16 and 18) is the vaccine for the national immunisation programme. In June 2015, the European Medicines Agency granted a marketing authorisation for Gardasil 9, intended for active immunisation against HPV diseases caused by 9 types of HPV (types 6, 11, 16, 18, 31, 33, 45, 52, 58). Gardasil 9 covers 5 more HPV types than Gardasil.